Recent developments in protein and peptide parenteral delivery approaches

Therapeutic Delivery

Volumn 5, Issue 3, 2014, Pages 337-365

  Patel, Ashaben ^a   Cholkar, Kishore ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON NANOTUBE; DRUG CARRIER; GLUCOSE; LIPOSOME; MANNOSE; NANOPARTICLE; PEPTIDE; PROTEIN;

BIOLOGICAL ACTIVITY; CHEMICAL MODIFICATION; COLLOID; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; GEL; GLYCOSYLATION; HEAT SENSITIVITY; HUMAN; MICELLE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; HUMANS; INFUSIONS, PARENTERAL; PEPTIDES; PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84896766008     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.5     Document Type: Review

References (175)

1. Biologics research promises bolster future. www.phrma.org/media/releases/ biologics-research-promises-bolster-future-medicine
2. Schiffter HA. The Delivery of Drugs-Peptides and Proteins. In: Comprehensive Biotechnology. Moo-Young M (Ed.). Elsevier BV, Amsterdam, The Netherlands, 587-604 (2011).
3. Depreter F, Pilcer G, Amighi K. Inhaled proteins: challenges and perspectives. Int. J. Pharm. 447(1-2), 251-280 (2013).
4. Siekmeier R, Scheuch G. Inhaled insulin-does it become reality? J. Physiol. Pharmacol. 59(Suppl. 6), 81-113 (2008).
5. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 64(7), 614-628 (2012).
6. Pawar R, Ben-Ari A, Domb AJ. Protein and peptide parenteral controlled delivery. Expert Opin. Biol. Ther. 4(8), 1203-1212 (2004).
7. Zalta AH, Sweeney CP, Zalta AK, Kaufman AH. Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants. Arch. Ophthalmol. 120(11), 1487-1493 (2002).
8. Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J. Pharm. Sci. 99(6), 2557-2575 (2010).
9. Kumar TR, Soppimath K, Nachaegari SK. Novel delivery technologies for protein and peptide therapeutics. Curr. Pharm. Biotechnol. 7(4), 261-276 (2006).
10. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97(10), 4167-4183 (2008).
11. Ryan SM, Mantovani G, Wang X, Haddleton DM, Brayden DJ. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin. Drug Deliv. 5(4), 371-383 (2008).
12. Parveen S, Sahoo SK. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin. Pharmacokinet. 45(10), 965-988 (2006).
13. Veronese FM, Morpurgo M. Bioconjugation in pharmaceutical chemistry. Farmaco 54(8), 497-516 (1999).
14. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22(5), 405-417 (2001).
15. Batra J, Robinson J, Mehner C et al. PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PloS ONE 7(11), e50028 (2012).
16. Da Silva Freitas D, Mero A, Pasut G. Chemical and enzymatic site specific PEGylation of hGH. Bioconjug. Chem. 24(3), 456-463 (2013).
17. Qiu H, Boudanova E, Park A et al. Site-specific PEGylation of human thyroid stimulating hormone to prolong duration of action. Bioconjug. Chem. 24(3), 408-418 (2013).
18. Freitas Dda S, Spencer PJ, Vassao RC, Abrahao-Neto J. Biochemical and biopharmaceutical properties of PEGylated uricase. Int. J. Pharm. 387(1-2), 215-222 (2010).
19. Xue X, Li D, Yu J, Ma G, Su Z, Hu T. Phenyl linker-induced dense PEG conformation improves the efficacy of C-terminally monoPEGylated staphylokinase. Biomacromolecules 14(2), 331-341 (2013).
20. Busch AP, Neebe M, Hampp N. PEGylation of membrane proteins like bacteriorhodopsin as a tool to increase their stability toward ethanol. J Phys. Chem. B 116(50), 14613-14617 (2012).
21. Palm T, Esfandiary R, Gandhi R. The effect of PEGylation on the stability of small therapeutic proteins. Pharm. Dev. Technol. 16(5), 441-448 (2011).
22. Tian H, Guo Y, Gao X, Yao W. PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation. J. Pharm. Pharmacol. 65(1), 53-63 (2013).
23. Elliott VL, Edge GT, Phelan MM et al. Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies. Mol. Pharm. 9(5), 1291-1301 (2012).
24. Bailon P, Palleroni A, Schaffer CA et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon a-2a for the treatment of hepatitis C. Bioconjug. Chem. 12(2), 195-202 (2001).
25. Kling J
26. Kaminskas LM, Ascher DB, Mcleod VM et al. PEGylation of interferon a2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases. J. Control. Release 168(2), 200-208 (2013).
27. Scaramuzza S, Tonon G, Olianas A et al. A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: production and physicochemical characterization. J. Control. Release 164(3), 355-363 (2012).
28. Akhtar J, Mallaredy V, Dandapat J, Maiti P, Sahoo SK, Singh S. PEGylation of an osteoclast inhibitory peptide: suitable candidate for the treatment of osteoporosis. Int. J. Pharm. 434(1-2), 429-436 (2012).
29. Zhang C, Fan K, Luo H et al. Characterization, efficacy, pharmacokinetics, and biodistribution of 5 kDa mPEG modified tetrameric canine uricase variant. Int.J. Pharm. 430(1-2), 307-317 (2012).
30. Kieseier BC, Calabresi PA. PEGylation of interferon-b-1a. a promising strategy in multiple sclerosis. CNS Drugs 26(3), 205-214 (2012).
31. Saenger S, Goeldner C, Frey JR et al. PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders. Growth Horm. IGF Res. 21(5), 292-303 (2011).
32. Cohan RA, Madadkar-Sobhani A, Khanahmad H et al. Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin. Int. J. Nanomed. 6, 1217-1227 (2011).
33. Bansal R, Post E, Proost JH, De Jager-Krikken A, Poelstra K, Prakash J. PEGylation improves pharmacokinetic profile, liver uptake and efficacy of interferon g in liver fibrosis. J. Control. Release 154(3), 233-240 (2011).
34. Miyaji Y, Kasuya Y, Furuta Y et al. Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats. Pharm. Res. 29(11), 3143-3155 (2012).
35. Barrack S, Mazzoni M: EP-2571896 A2 (2011).
36. Fan K, Hu C, Luo H et al.: EP-2684950 A1 (2012).
37. Gregoriadis G, Jain S, Papaioannou I, Laing P. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int. J. Pharm. 300(1-2), 125-130 (2005).
38. Gregoriadis G, Fernandes A, Mital M, Mccormack B. Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell. Mol. Life Sci. 57(13-14), 1964-1969 (2000).
39. Fernandes AI, Gregoriadis G. Synthesis, characterization and properties of sialylated catalase. Biochim. Biophys. Acta 1293(1), 90-96 (1996).
40. Fernandes AI, Gregoriadis G. Polysialylated asparaginase: preparation, activity and pharmacokinetics. Biochim. Biophys. Acta 1341(1), 26-34 (1997).
41. Fernandes AI, Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int. J. Pharm. 217(1-2), 215-224 (2001).
42. Jain S, Hreczuk-Hirst DH, Mccormack B et al. Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim. Biophys. Acta 1622(1), 42-49 (2003).
43. Bolt G, Bjelke JR, Hermit MB, Hansen L, Karpf DM, Kristensen C. Hyperglycosylation prolongs the circulation of coagulation factor ix. J. Thromb. Haemost. 10(11), 2397-2398 (2012).
44. Ceaglio N, Etcheverrigaray M, Kratje R, Oggero M. Novel long-lasting interferon a derivatives designed by glycoengineering. Biochimie 90(3), 437-449 (2008).
45. Ceaglio N, Etcheverrigaray M, Kratje R, Oggero M. Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon a mutein. Biochimie 92(8), 971-978 (2010).
46. Kosloski MP, Miclea RD, Balu-Iyer SV. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J. 11(3), 424-431 (2009).
47. Powell J, Gurk-Turner C. Darbepoetin a (Aranesp). Proc. (Bayl. Univ. Med. Cent.)15(3), 332-335 (2002).
48. Lipoxen PLC. www.bionity.com/en/companies/12278/lipoxen-plc.html
49. Opanasopit P, Shirashi K, Nishikawa M, Yamashita F, Takakura Y, Hashida M. In vivo recognition of mannosylated proteins by hepatic mannose receptors and mannan-binding protein. Am. J. Physiol. Gastrointest. Liver Physiol. 280(5), G879-g889 (2001).
50. Maria I, Korontzi A P, Kouerinis I, Lazaris AC, Theodoropoulos G, Zografos G. Redox state and the potential role of antioxidant compounds in liver ischemia/reperfusion injury. Int. J. Med. Sci. 2(7), 200-209 (2010).
51. Fujita T, Furitsu H, Nishikawa M, Takakura Y, Sezaki H, Hashida M. Therapeutic effects of superoxide dismutase derivatives modified with mono-or polysaccharides on hepatic injury induced by ischemia/reperfusion. Biochem. Biophysical Res. Comm. 189(1), 191-196 (1992).
52. Kel J, Oldenampsen J, Luca M, Drijfhout JW, Koning F, Nagelkerken L. Soluble mannosylated myelin peptide inhibits the encephalitogenicity of autoreactive T cells during experimental autoimmune encephalomyelitis. Am. J. Path. 170(1), 272-280 (2007).
53. Tan ML, Choong PF, Dass CR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 31(1), 184-193 (2010).
54. Beg S, Samad A, Nazish I et al. Colloidal drug delivery systems in vaccine delivery. Curr. Drug Targets 14(1), 123-137 (2013).
55. Ye M, Kim S, Park K. Issues in long-term protein delivery using biodegradable microparticles. J. Control. Release 146(2), 241-260 (2010).
56. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J. Control. Release 90(3), 261-280 (2003).
57. Van De Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17(10), 1159-1167 (2000).
58. Shi Y, Li LC. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin. Drug Deliv. 2(6), 1039-1058 (2005).
59. Schwach G, Oudry N, Delhomme S, Luck M, Lindner H, Gurny R. Biodegradable microparticles for sustained release of a new GnRH antagonist-part I. Screening commercial PLGA and formulation technologies. Eur. J. Pharm. Biopharm. 56(3), 327-336 (2003).
60. Schwach G, Oudry N, Giliberto JP et al. Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance. Eur. J. Pharm. Biopharm. 57(3), 441-446 (2004).
61. Li Z, Li L, Liu Y et al. Development of interferon a-2b microspheres with constant release. Int. J. Pharm. 410(1-2), 48-53 (2011).
62. 2/water interface and upon water-in-oil-in-water encapsulation in PLGA microspheres. J. Control. Release 89(1), 71-85 (2003).
63. Malik DK, Baboota S, Ahuja A, Hasan S, Ali J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 4(2), 141-151 (2007).
64. Bossart J. Benchmarking drug delivery-defining product benefit and value. Drug Deliv. Technol. 5(2), 22 (2005).
65. Giteau A, Venier-Julienne MC, Marchal S et al. Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres. Eur. J. Pharm. Biopharm. 70(1), 127-136 (2008).
66. Montalvo-Ortiz BL, Sosa B, Griebenow K. Improved enzyme activity and stability in polymer microspheres by encapsulation of protein nanospheres. AAPS PharmSciTech 13(2), 632-636 (2012).
67. Kim TH, Jiang HH, Park CW et al. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity. J. Control. Release 150(1), 63-69 (2011).
68. Hinds KD, Campbell KM, Holland KM, Lewis DH, Piche CA, Schmidt PG. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis. J. Control. Release 104(3), 447-460 (2005).
69. Garbayo E, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. Eur. J. Pharm. Biopharm. 69(3), 844-851 (2008).
70. Ji Y, Dong W, Wanga X et al. Studies on MEP421 PLGA microspheres: preparation and drug release. Asian J. Pharm. Sci. 3(5), 211-216 (2008).
71. Park EJ, Na DH, Lee KC. In vitro release study of mono-PEGylated growth hormone-releasing peptide-6 from PLGA microspheres. Int. J. Pharm. 343(1-2), 281-283 (2007).
72. Wu H, Wang S, Fang H, Zan X, Zhang J, Wan Y. Chitosan-polycaprolactone copolymer microspheres for transforming growth factor-b1 delivery. Colloids Surf. B Biointerfaces 82(2), 602-608 (2011).
73. Yin D, Lu Y, Zhang H et al. Preparation of glucagon-like peptide-1 loaded PLGA microspheres: characterizations, release studies and bioactivities in vitro/in vivo. Chem. Pharm. Bull. 56(2), 156-161 (2008).
74. Park W, Kim D, Kang HC, Bae YH, Na K. Multi-arm histidine copolymer for controlled release of insulin from poly(lactide-co-glycolide) microsphere. Biomaterials 33(34), 8848-8857 (2012).
75. Manoharan C, Singh J. Evaluation of polyanhydride microspheres for basal insulin delivery: effect of copolymer composition and zinc salt on encapsulation, in vitro release, stability, in vivo absorption and bioactivity in diabetic rats. J. Pharm. Sci. 98(11), 4237-4250 (2009).
76. Liu B, Dong Q, Wang M et al. Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres. Chem. Pharm. Bull. 58(11), 1474-1479 (2010).
77. Formiga FR, Pelacho B, Garbayo E et al. Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration. J. Control. Release 173, 132-139 (2014).
78. Rubinstein I, Ikezaki H, Onyuksel H. Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters. Int. J. Pharm. 316(1-2), 144-147 (2006).
79. Park SJ, Choi SG, Davaa E, Park JS. Encapsulation enhancement and stabilization of insulin in cationic liposomes. Int. J. Pharm. 415(1-2), 267-272 (2011).
80. Behera T, Swain P, Sahoo SK. Antigen in chitosan coated liposomes enhances immune responses through parenteral immunization. Int. Immunopharmacol. 11(8), 907-914 (2011).
81. Li H, Yang L, Cheng G, Wei HY, Zeng Q. Encapsulation, pharmacokinetics and tissue distribution of interferon a-2b liposomes after intramuscular injection to rats. Arch. Pharm. Res. 34(6), 941-948 (2011).
82. Wang T, Gao L, Quan D. Multivesicular liposome (MVL) sustained delivery of a novel synthetic cationic GnRH antagonist for prostate cancer treatment. J. Pharm. Pharmacol. 63(7), 904-910 (2011).
83. Meng M, Liu Y, Wang YB et al. Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes. J. Control. Release 128(2), 113-119 (2008).
84. Tomar L, Tyagi C, Kumar M et al. In vivo evaluation of a conjugated poly(lactide-ethylene glycol) nanoparticle depot formulation for prolonged insulin delivery in the diabetic rabbit model. Int. J. Nanomed. 8, 505-520 (2013).
85. Vasudev SS, Ahmad S, Parveen R et al. Formulation of PEG-ylated L-asparaginase loaded poly (lactide-co-glycolide) nanoparticles: influence of PEGylation on enzyme loading, activity and in vitro release. Die Pharmazie 66(12), 956-960 (2011).
86. Qi C, Chen Y, Jing QZ, Wang XG. Preparation and characterization of catalase-loaded solid lipid nanoparticles protecting enzyme against proteolysis. Int. J. Mol. Sci. 12(7), 4282-4293 (2011).
87. Qi C, Chen Y, Huang JH, Jin QZ, Wang XG. Preparation and characterization of catalase-loaded solid lipid nanoparticles based on soybean phosphatidylcholine. J. Sci. Food Agric. 92(4), 787-793 (2012).
88. Sung HW, Lin YH, Liang H, Tu H: US7282194 B2 (2007).
89. Sokoll K, Melinda J: WO2013033838 A1 (2013).
90. Jin T, Hu Z, Yuan W: WO2013083041 A1 (2013).
91. Kim BO, Seo MH, Yi Y W, Yoon HJ: WO2012087051 A2. (2012).
92. Yang X, Patel A, Vadlapudi AD, Mitra AK. Application of Nanotechnology in Ocular Drug De l iver y. In: Treatise on Ocular Drug Delivery. Mitra AK (Ed.). Bentham Science Publishers, Sharjah, United Arab Emirates, 253-284 (2013).
93. Yadav SC, Kumari A, Yadav R. Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides 32(1), 173-187 (2011).
94. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J. Pharmacol. 2(2), 47-64 (2013).
95. Glowka E, Sapin-Minet A, Leroy P, Lulek J, Maincent P. Preparation and in vitro-in vivo evaluation of salmon calcitonin-loaded polymeric nanoparticles. J. Microencapsul. 27(1), 25-36 (2010).
96. Kumar PS, Saini TR, Chandrasekar D, Yellepeddi VK, Ramakrishna S, Diwan PV. Novel approach for delivery of insulin loaded poly(lactide-co-glycolide) nanoparticles using a combination of stabilizers. Drug Deliv. 14(8), 517-523 (2007).
97. Gaudana R, Khurana V, Parenky A, Mitra AK. Encapsulation of protein-polysaccharide HIP complex in polymeric nanoparticles. J. Drug Deliv. 2011, 458128 (2011).
98. Shi K, Cui F, Yamamoto H, Kawashima Y. Investigation of drug loading and in vitro release mechanisms of insulin-lauryl sulfate complex loaded PLGA nanoparticles. Die Pharmazie 63(12), 866-871 (2008).
99. Yang L, Cui F, Shi K, Cun D, Wang R. Design of high payload PLGA nanoparticles containing melittin/sodium dodecyl sulfate complex by the hydrophobic ion-pairing technique. Drug Dev. Ind. Pharm. 35(8), 959-968 (2009).
100. Choi SH, Park TG. Hydrophobic ion pair formation between leuprolide and sodium oleate for sustained release from biodegradable polymeric microspheres. Int. J. Pharm. 203(1-2), 193-202 (2000).
101. Gaudana R, Gokulgandhi M, Khurana V, Kwatra D, Mitra AK. Design and evaluation of a novel nanoparticulate-based formulation encapsulating a HIP complex of lysozyme. Pharm. Dev. Technol. 18(3), 752-759 (2013).
102. Peng Q, Zhang ZR, Gong T, Chen GQ, Sun X. A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. Biomaterials 33(5), 1583-1588 (2012).
103. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 50(1), 161-177 (2000).
104. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47(2-3), 165-196 (2001).
105. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59(6), 478-490 (2007).
106. Ravi S, Shukla ZC, Kun Cheng. Strategies of Drug Targeting. In: Advanced Drug Delivery. Mitra A, Lee CH, Cheng K (Eds). John Wiley and Sons, Inc., Hoboken, NJ, USA, 105-120 (2013).
107. Salmaso S, Elvassore N, Bertucco A, Caliceti P. Production of solid lipid submicron particles for protein delivery using a novel supercritical gas-assisted melting atomization process. J. Pharm. Sci. 98(2), 640-650 (2009).
108. Huang C, Jin H, Qian Y et al. Hybrid melittin cytolytic peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo. ACS Nano 7(7), 5791-5800 (2013).
109. Zhang L, Zhao ZL, Wei XH, Liu JH. Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles. Int. J. Nanomed. 8, 601-610 (2013).
110. Gallarate M, Battaglia L, Peira E, Trotta M. Peptide-loaded solid lipid nanoparticles prepared through coacervation technique. Int. J. Chem. Eng. 2011, 132435 (2011).
111. Yang R, Gao RC, Cai CF et al. Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide. Chem. Pharm. Bull. 58(9), 1195-1202 (2010).
112. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int. J. Nanomed. 2(4), 595-607 (2007).
113. Walde P, Ichikawa S. Enzymes inside lipid vesicles: preparation, reactivity and applications. Biomol. Eng. 18(4), 143-177 (2001).
114. Swaminathan J, Ehrhardt C. Liposomal delivery of proteins and peptides. Expert Opin. Drug Deliv. 9(12), 1489-1503 (2012).
115. Stevenson RW, Patel HM, Parsons JA, Ryman BE. Prolonged hypoglycemic effect in diabetic dogs due to subcutaneous administration of insulin in liposomes. Diabetes 31(6 Pt 1), 506-511 (1982).
116. Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K. Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice. Drug Dev. Ind. Pharm. 29 (10), 1149-1153 (2003).
117. Fukunaga M, Miller MM, Deftos LJ. Factors influencing the enhanced hypocalcemic action of liposome-entrapped calcitonin. Calcif. Tissue Int. 47(6), 373-377 (1990).
118. Mantripragada S. A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog. Lipid. Res. 41(5), 392-406 (2002).
119. Vyas SP, Rawat M, Rawat A, Mahor S, Gupta PN. PEGylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon a. Drug Dev. Ind. Pharm. 32(6), 699-707 (2006).
120. Ramprasad MP, Anantharamaiah GM, Garber DW, Katre NV. Sustained-delivery of an apolipoprotein E-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels. J. Control. Release 79(1-3), 207-218 (2002).
121. Katre NV, Asherman J, Schaefer H, Hora M. Multivesicular liposome (DepoFoam) technology for the sustained delivery of insulin-like growth factor-I (IGF-I). J. Pharm. Sci. 87(11), 1341-1346 (1998).
122. Ramprasad MP, Amini A, Kararli T, Katre N V. The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes. Int. J. Pharm. 261(1-2), 93-103 (2003).
123. Langston MV, Ramprasad MP, Kararli TT, Galluppi GR, Katre NV. Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam). J. Control. Release 9(1), 87-99 (2003).
124. Qiu J, Wei XH, Geng F, Liu R, Zhang JW, Xu YH. Multivesicular liposome formulations for the sustained delivery of interferon a-2b. Acta Pharmacol. Sinica 26(11), 1395-1401 (2005).
125. Ye Q, Asherman J, Stevenson M, Brownson E, Katre N V. DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. J. Control. Release 64(1-3), 155-166 (2000).
126. Howell SB. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. Cancer J. 7(3), 219-227 (2001).
127. Kim JY, Kim JK, Park JS, Byun Y, Kim CK. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 30(29), 5751-5756 (2009).
128. Yatuv R, Robinson M, Dayan I, Baru M. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. Expert Opin. Drug Deliv. 7(2), 187-201 (2010).
129. Yatuv R, Robinson M, Dayan-Tarshish I, Baru M. The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia. Int. J. Nanomed. 5, 581-591 (2010).
130. Mali N, Jadhav S, Karpe M, Kadam V. Carbon nanotubes as carriers for delivery of bioactive and therapeutic agents: an overview. Int. J. Pharm. Sci. 3(3), 45-52 (2011).
131. Garmaroudi FS, Vahdati RAR. Functionalized CNTs for delivery of therapeutics. Int. J. Nano Dim. 1(2), 89-102 (2010).
132. Elhissi AM, Ahmed W, Hassan IU, Dhanak VR, D'Emanuele A. Carbon nanotubes in cancer therapy and drug delivery. J. Drug Deliv. 2012, 837327 (2012).
133. Shi Kam NW, Jessop TC, Wender PA, Dai H. Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells. J. Am. Chem. Soc. 126(22), 6850-6851 (2004).
134. Kam NW, Dai H. Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J. Am. Chem. Soc. 127(16), 6021-6026 (2005).
135. Weng X, Wang M, Ge J et al. Carbon nanotubes as a protein toxin transporter for selective HER2-positive breast cancer cell destruction. Mol. Biosyst. 5(10), 1224-1231 (2009).
136. Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Curr. Opin. Chem. Biol. 9(6), 674-679 (2005).
137. Pantarotto D, Partidos CD, Hoebeke J et al. Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem. Biol. 10(10), 961-966 (2003).
138. Meng J, Meng J, Duan J et al. Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy. Small 4(9), 1364-1370 (2008).
139. Yandar N, Pastorin G, Prato M, Bianco A, Patarroyo ME, Lozano JM. Immunological profile of a Plasmodium vivax AMA-1 N-terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model. Vaccine 26(46), 5864-5873 (2008).
140. Villa CH, Dao T, Ahearn I et al. Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano 5(7), 5300-5311 (2011).
141. Cholkar K, Patel A, Vadlapudi AD, Mitra AK. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Patents Nanomed. 2(2), 82-95 (2012).
142. Shi Y, Huang W, Liang R et al. Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG-PLA micelle. Int. J. Nanomed. 8, 1-11 (2013).
143. Lim SB, Rubinstein I, Onyuksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles. Int. J. Pharm. 356(1-2), 345-350 (2008).
144. Heffernan MJ, Murthy N. Disulfide-crosslinked polyion micelles for delivery of protein therapeutics. Ann. Biomed. Eng. 37(10), 1993-2002 (2009).
145. Wang T, Petrenko VA, Torchilin VP. Optimization of landscape phage fusion protein-modified polymeric PEG-PE micelles for improved breast cancer cell targeting. Nanomed. Nanotechnol. 1-7 (2012).
146. Jiang M, Wu Y, Yong H, Jun N. Micelles formed by self-assembly of hyperbranched poly[(amine-ester)-co-(D, L-lactide)] (HPAE-co-PLA) copolymers for protein drug delivery. Polymer Int. 58(1), 31-39 (2009).
147. Banerjee A, Onyuksel H. Human pancreatic polypeptide in a phospholipid-based micellar formulation. Pharm. Res. 29(6), 1698-1711 (2012).
148. Kuzmis A, Lim SB, Desai E et al. Micellar nanomedicine of human neuropeptide Y. Nanomedicine 7(4), 464-471 (2011).
149. Lim SB, Rubinstein I, Sadikot RT, Artwohl JE, Onyuksel H. A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles. Pharm. Res. 28(3), 662-672 (2011).
150. Wang F, Li X, Zhou Y et al. Nanoscaled polyion complex micelles for targeted delivery of recombinant hirudin to platelets based on cationic copolymer. Mol. Pharm. 7(3), 718-726 (2010).
151. Bonacucina G, Cespi M, Mencarelli G, Giorgioni G, Palmieri GF. Thermosensitive self-assembling block copolymers as drug delivery systems. Polymers 3, 779-811 (2011).
152. Al-Tahami K, Singh J. Smart polymer based delivery systems for peptides and proteins. Recent Pat. Drug Deliv. Formul. 1(1), 65-71 (2007).
153. Chen S, Singh J. Controlled release of growth hormone from thermosensitive triblock copolymer systems: in vitro and in vivo evaluation. Int. J. Pharm. 352(1-2), 58-65 (2008).
154. Liu Y, Lu WL, Wang JC et al. Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic F127 hydrogel for subcutaneous administration: in vitro and in vivo characterization. J. Control. Release 117(3), 387-395 (2007).
155. ® F127 parenteral formulations. Dissol. Technol. 14, 15-26 (2007).
156. Akash MS, Rehman K, Sun H, Chen S. Assessment of release kinetics, stability and polymer interaction of poloxamer 407-based thermosensitive gel of interleukin-1 receptor antagonist. Pharm. Dev. Technol. 19(3), 278-284 (2013).
157. Akash MS, Rehman K, Sun H, Chen S. Sustained delivery of IL-1Ra from PF127-gel reduces hyperglycemia in diabetic GK-rats. PloS ONE 8(2), e55925 (2013).
158. Akash MS, Rehman K, Li N, Gao JQ, Sun H, Chen S. Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials. Pharm. Res. 29(12), 3475-3485 (2012).
159. Park MR, Chun C, Ahn SW, Ki MH, Cho CS, Song SC. Sustained delivery of human growth hormone using a polyelectrolyte complex-loaded thermosensitive polyphosphazene hydrogel. J. Control. Release 147(3), 359-367 (2010).
160. Jabarian EL, Rouini MR, Atyabi F, Foroumadi A, Nassiri SM, Dinarvand R. In vitro and in vivo evaluation of an in situ gel forming system for the delivery of PEGylated octreotide. Eur. J. Pharm. Sci. 48(1-2), 87-96 (2013).
161. Hiwale P, Lampis S, Conti G et al. In vitro release of lysozyme from gelatin microspheres: effect of cross-linking agents and thermoreversible gel as suspending medium. Biomacromolecules 12(9), 3186-3193 (2011).
162. Al-Tahami K, Oak M, Mandke R, Singh J. Basal level insulin delivery: in vitro release, stability, biocompatibility, and in vivo absorption from thermosensitive triblock copolymers. J. Pharm. Sci. 100(11), 4790-4803 (2011).
163. Khodaverdi E, Tafaghodi M, Ganji F, Abnoos K, Naghizadeh H. In vitro insulin release from thermosensitive chitosan hydrogel. AAPS PharmSciTech 13(2), 460-466 (2012).
164. Al-Tahami K, Oak M, Singh J. Controlled delivery of basal insulin from phase-sensitive polymeric systems after subcutaneous administration: in vitro release, stability, biocompatibility, in vivo absorption, and bioactivity of insulin. J. Pharm. Sci. 100(6), 2161-2171 (2011).
165. Wu Q J, Zhu XC, Xiao X et al. A novel vaccine delivery system: biodegradable nanoparticles in thermosensitive hydrogel. Growth Factors 29(6), 290-297 (2011).
166. Gong CY, Shi S, Peng XY et al. Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity. Growth Factors 27(6), 377-383 (2009).
167. Tang Y, Singh J. Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies. Pharm. Res. 27(2), 272-284 (2010).
168. Park MR, Chun C, Ahn SW, Ki MH, Cho CS, Song SC. Cationic and thermosensitive protamine conjugated gels for enhancing sustained human growth hormone delivery. Biomaterials 31(6), 1349-1359 (2010).
169. Seo BB, Park MR, Chun C, Lee JY, Song SC. The biological efficiency and bioavailability of human growth hormone delivered using injectable, ionic, thermosensitive poly(organophosphazene)-polyethylenimine conjugate hydrogels. Biomaterials 32(32), 8271-8280 (2011).
170. Oak M, Singh J. Controlled delivery of basal level of insulin from chitosan-zinc-insulin-complex-loaded thermosensitive copolymer. J. Pharm. Sci. 101(3), 1079-1096 (2012).
171. Park MR, Seo BB, Song SC. Dual ionic interaction system based on polyelectrolyte complex and ionic, injectable, and thermosensitive hydrogel for sustained release of human growth hormone. Biomaterials 34(4), 1327-1336 (2013).
172. Qiao M, Chen D, Ma X, Hu H. Sustained release of bee venom peptide from biodegradable thermosensitive PLGA-PEG-PLGA triblock copolymer-based hydrogels in vitro. Die Pharm. 61(3), 199-202 (2006)
173. US FDA regulatory information. www.fda.gov/regulatoryinformation/ legislation/default.htm
174. US FDA guidance compliance. www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/duidances/ucm338856.pdf
175. US FDA regulatory information www.fda.dov/downloads/ regulatoryinformation/guidances/uc m129171.pdf